This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Mar;9(1):68-71.

doi: 10.1016/j.ebcm.2005.01.008.

PCI with bivalirudin and provisional GP IIb/IIIa inhibition is more cost-effective than heparin plus routine GP IIb/IIIa inhibition. Commentary

William B Hillegass¹

Affiliations

PMID: 16379993
DOI: 10.1016/j.ebcm.2005.01.008

Comment

PCI with bivalirudin and provisional GP IIb/IIIa inhibition is more cost-effective than heparin plus routine GP IIb/IIIa inhibition. Commentary

William B Hillegass. Evid Based Cardiovasc Med. 2005 Mar.

. 2005 Mar;9(1):68-71.

doi: 10.1016/j.ebcm.2005.01.008.

Author

William B Hillegass¹

Affiliation

¹ University of Alabama at Birmingham, USA.

PMID: 16379993
DOI: 10.1016/j.ebcm.2005.01.008

No abstract available

PubMed Disclaimer

Comment on

Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ. Cohen DJ, et al. J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800. doi: 10.1016/j.jacc.2004.05.085. J Am Coll Cardiol. 2004. PMID: 15519009 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal